RWF_D6020C00001

A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination with MEDI4736 in Subjects with Advanced Malignancies

To evaluate the safety and tolerability of MEDI0680 (AMP-514) given in combination with MEDI4736.

Inclusion Criteria:

•Eastern Cooperative Oncology Group performance status of 0-1

•Adequate organ function

Exclusion Criteria:

•Concurrent enrollment in another clinical study, unless in follow-up period or it is an observational study

•Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
Phase I
NCT02118337
Oncology
Multiple Tumor Types
Rachel Sanborn, M.D.
MedImmune, LLC
Kim Sutcliffe
  • Oncology and Hematology Care Eastside